6.00
8.50%
+0.47
After Hours:
6.08
0.08
+1.33%
Travere Therapeutics Inc stock is currently priced at $6.00, with a 24-hour trading volume of 1.87M.
It has seen a +8.50% increased in the last 24 hours and a -17.92% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $5.53 pivot point. If it approaches the $6.22 resistance level, significant changes may occur.
Previous Close:
$5.53
Open:
$5.54
24h Volume:
1.87M
Market Cap:
$456.65M
Revenue:
$198.84M
Net Income/Loss:
$-111.40M
P/E Ratio:
-1.3274
EPS:
-4.52
Net Cash Flow:
$-322.28M
1W Performance:
+10.09%
1M Performance:
-17.92%
6M Performance:
-10.71%
1Y Performance:
-73.46%
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888 969 7879
Address
3611 Valley Centre Drive, Suite 300, San Diego
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Sep-06-23 | Resumed | Evercore ISI | Outperform |
Jul-21-23 | Initiated | JP Morgan | Overweight |
Jun-07-23 | Resumed | Piper Sandler | Neutral |
May-22-23 | Initiated | TD Cowen | Outperform |
May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
Mar-01-23 | Initiated | Guggenheim | Buy |
Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
Dec-14-22 | Initiated | Stifel | Hold |
Dec-05-22 | Initiated | Wells Fargo | Overweight |
Sep-21-22 | Initiated | Bryan Garnier | Sell |
Jul-14-22 | Resumed | Canaccord Genuity | Buy |
Mar-31-22 | Initiated | Piper Sandler | Overweight |
Feb-28-22 | Initiated | H.C. Wainwright | Buy |
May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Analysts Estimate Arcturus Therapeutics (ARCT) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Travere Therapeutics to Report First Quarter 2024 Financial Results
GlobeNewswire Inc.
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
GlobeNewswire Inc.
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
Benzinga
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
GlobeNewswire Inc.
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
GlobeNewswire Inc.
Travere Therapeutics Inc Stock (TVTX) Financials Data
Travere Therapeutics Inc (TVTX) Revenue 2024
TVTX reported a revenue (TTM) of $198.84 million for the quarter ending December 31, 2023, a +24.22% rise year-over-year.
Travere Therapeutics Inc (TVTX) Net Income 2024
TVTX net income (TTM) was -$111.40 million for the quarter ending December 31, 2023, a +60.00% increase year-over-year.
Travere Therapeutics Inc (TVTX) Cash Flow 2024
TVTX recorded a free cash flow (TTM) of -$322.28 million for the quarter ending December 31, 2023, a -50.00% decrease year-over-year.
Travere Therapeutics Inc (TVTX) Earnings per Share 2024
TVTX earnings per share (TTM) was -$1.61 for the quarter ending December 31, 2023, a +63.16% growth year-over-year.
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):